ASPIRE interferon beta 1-b in combination with azathioprine for secondary progressive multiple sclerosis: a 2-year double blind, randomized, multicentre, pilot study. Safety and drop-outs data at 21 month of enrollement
L. Manneschi, E. Montanari(University of Milan), A. Ghezzi(Azienda Ospedaliera Sant’Antonio Abate di Gallarate), Elio Scarpini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), E. Merelli(University of Pisa), Ilaria Pesci, Paola Cavalla, Luca Durelli(University of Turin), L. Motti(Santa Maria Nuova Hospital), M. R. Tola(Vita-Salute San Raffaele University), Leandro Provinciali(Ospedali Riuniti di Ancona), D. Caputo, Maria Giovanna Marrosu(University of Cagliari)
Unknown
January 1, 2006
Cited by 0
Related Papers
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
|The Lancet|2001|1.1k
Multiple Sclerosis Severity Score
|Neurology|2005|959
Genome-wide Analyses Identify KIF5A as a Novel ALS Gene
|Neuron|2018|724
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
|The Lancet|2002|552
Evidence of early cortical atrophy in MS
|Neurology|2003|485